BIOMAT Database Logo BIOMAT Database Logo

Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. 1996

C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Unidad Metabólica, Fundación Jiménez Díaz Avda Reyes Católicos 2, 28040 Madrid, Spain.

The aim of this work was to evaluate the response of different biochemical bone markers to tiludronate administration in Paget's disease of bone. Ten patients (five men and five women), 56-77 years old (67 +/- 6.5), were treated for 3 months with tiludronate tablets (400 mg/day). Bone formation markers: alkaline phosphatase (AP), bone alkaline phosphatase (bAP), osteocalcin (BGP), and procollagen I carboxyterminal propeptide (PICP) in serum; and bone resorption markers: serum cross-linked carboxyterminal telopeptides of type I collagen (ICTP), urinary hydroxyproline/creatinine (Hyp/Cr), pyridinoline/Cr (Pyr/Cr), and alpha-1 collagen chain products degradation (CrossLaps) were assessed. Samples were taken before and at monthly intervals for 3 months after treatment began. The results of the present work show that serum AP and bAP are sensitive and reliable biochemical markers of bone formation in the follow-up of tiludronate in this disease. Serum PICP shows less sensitivity than serum AP, and serum BGP is not indicated as biochemical marker in these types of studies. Urinary hydroxyproline seems to be the most reliable biochemical marker of bone resorption. More studies should be performed with urinary Pyr and CrossLaps determinations. Serum ICTP is not adequate for the follow-up of tiludronate treatment in Paget's disease of bone.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010001 Osteitis Deformans A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry. Paget's Disease of Bone,Osseous Paget's Disease,Paget Disease of Bone,Paget Disease, Bone,Pagets Disease, Bone
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates

Related Publications

C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Tiludronate for Paget's disease of bone.
July 1997, The Medical letter on drugs and therapeutics,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Paget's disease of bone treated with a five day course of oral tiludronate.
January 1993, Annals of the rheumatic diseases,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Tiludronate therapy for Paget's disease of bone.
November 1995, Bone,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Biochemical markers of bone turnover in Paget's disease.
January 1981, Metabolic bone disease & related research,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Biochemical markers of bone turnover in Paget's disease of bone.
May 1999, Bone,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Biochemical markers of bone turnover in Paget's disease of bone.
October 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Biochemical markers in the management of patients with metastatic bone disease.
August 1999, Clinical chemistry,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
[Use of biochemical markers of bone turnover in Paget's disease of bone].
January 2001, Annales de biologie clinique,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
January 2007, Clinical and experimental rheumatology,
C de la Piedra, and A Rapado, and E M Díaz Diego, and M A Díaz Martín, and C Aguirre, and E López Gavilanes, and M Díaz Curiel
The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
November 1995, Bone,
Copied contents to your clipboard!